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The Human Genome Project Aims for 2003
Laurie Goodman1
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11743 USA
Bold is the operative word for the
goals in the new five-year plan for the
U.S. Human Genome Project as pre-
sented at the National Human Genome
Research Institute (NHGRI) advisory
council meeting on September 14, 1998.
(See Box 1 for an overview of the 5-year
plan. The complete plan is published in
the October 23, 1998 issue of Science.)
The plan itself includes such words as
‘‘ambitious’’ and even ‘‘audacious,’’ re-
flecting the committee’s own perception
that the agenda is one that will require
extreme diligence and effort to achieve.
The most notable point is the call for the
completion of the human genome se-
quence in the year 2003—a full 2 years
earlier than originally planned and cor-
responding to the 50th anniversary of
the discovery of the double helix struc-
ture of DNA (Watson and Crick 1953).
The proposal was approved by the
NHGRI council and by the U.S. Depart-
ment of Energy (DOE); human genome
project research in the U.S. is sponsored
jointly by the NHGRI at the National In-
stitutes of Health (NIH) and the Office of
Biological Environmental Research at
the DOE. Approximately two-thirds of
the human genome sequence is esti-
mated to be completed by NIH- and
DOE-funded projects and the remainder
by international Wellcome Trust-funded
projects.
In addition to the new time frame for
the completion of the human genome
sequence, the plan also covers new
agendas for the (often overlooked) wide
range of other areas embraced under the
heading of the Human Genome Project.
New plans are in effect for supporting
and developing novel technology (from
sequencing hardware to computer soft-
ware); setting goals for model organ-
isms; devising genomic resources, such
as cDNA libraries, for the broader bio-
logical community; educating and es-
tablishing new resources in manpower;
and continuing programs to investigate
the impact of this new genetic informa-
tion on the ethical, legal, and social as-
pects of the population.
2003 or Bust
The goal of completing the human ge-
nome sequence by 2003 instead of 2005
is what is catching most of the attention
from the press and public. Most wonder
if this maneuver is simply a response to
the claims by private sector companies
that they will provide a sequence of the
human genome by 2003—2 years ahead
of the initial 2005 date set by the pub-
licly funded genome initiative.
Francis Collins (Director, NHGRI) ad-
mits that the plan presented in May by
the collaborative venture between Craig
Venter and Perkin-Elmer (Celera Ge-
nomics Corp.), followed by that an-
nounced in August by Incyte Pharma-
ceuticals to sequence the entire human
genome by the year 2003, certainly had
a ‘‘crystallizing effect.’’ Collins adds,
however, that ‘‘the ability to do this [in
publicly funded genome centers] is
clearly here, and if Celera decided not to
do it [pursue sequencing the human ge-
nome by 2003] tomorrow, we wouldn’t
suddenly decide against going ahead
with this bolder plan.’’
Richard Gibbs (Baylor College of
Medicine Sequencing Center, Houston,
TX) likewise pointed out that the pub-
licly funded project has been poised to
make such a move for some time. Previ-
ous publications and announcements
have made it clear that the public
project is already 2 years ahead of sched-
ule (Collins 1995)—making 2003 as a
completion date a logical outcome.
Many in the private sector, however, re-
main convinced that the faster agenda
can be nothing other than a response to
their plans.
To a great extent, whether or not the
2003 mark for the complete sequence is
the publicly funded project’s response to
private sector plans is rather unimpor-
tant when taken out of context with re-
spect to what the scientific community
will be getting. If the publicly funded
projects were sacrificing quality and
completeness for speed in a response to
private sector plans, this would indeed
be unacceptable. One of the clear aims
of the publicly funded projects has been
their target of a highly accurate (error
rate = 1⁄10,000), long-range contiguous se-
quence for the human genome. That
this remains the final goal of the public
project even with the earlier 2003 date is
the most important factor for the scien-
tific community.
There are two points in this 5-year
agenda that are expressly new to the
overall human genome sequencing
plan. One point is that roughly one-
third of the sequence, that is, approxi-
mately 1 Gb of sequence with several
contigs of no less than 20 Mb in length,
will be finished by 2001. This is achiev-
able because of advances in technology
over the last 5 years and expected ad-
vances in the upcoming years as well as
the anticipated scale-up of the best
methodologies for sequencing as deter-
mined over the last 5 years. A peer-
review process will also be set in place to
prioritize specific regions to be finished
first. Such ranking of genome regions
will reflect the needs of the interna-
tional scientific community and should
dovetail with the sequencing strategies
at the time, such that large-scale se-
quencing disruptions are at a minimum.
The addition of a selection process for
sequencing specific areas of interest or
gene-rich regions may reflect a desire to
provide early public availability of re-
gions that may otherwise end up solely
in the hands of the private sector; con-
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Box 1. Human Genome Project Goals for 1998–2003
c Goal 1: The Human Genome Sequence
a. Complete the human genome sequence by end of 2003
b. Complete one-third of the human genome by end of 2001
c. 90% coverage of genome in working draft with mapped clones by end of 2001
d. Make entire sequence freely accessible
c Goal 2: Sequence Technology
a. Increase throughput and reduce cost of sequencing technology
b. Support novel technology research that can lead to significant improvement in sequencing technology
c. Development of methods for introduction of new technologies into sequencing process
c Goal 3: Sequence Variation
a. Develop technologies for rapid, large-scale identification of SNPs or other DNA sequence variants
b. Identify common variants in coding regions of the majority of identified genes
c. Create 100,000-marker SNP map of the human genome
d. Develop intellectual foundations for studies of sequence variation
e. Create public DNA sample and cell line resources that are totally anonymous and carry appropriate restrictions to
maintain their anonymity (Establishment of separate, appropriately marked sample resources after taking into account
issues examined in Goal 6)
c Goal 4: Functional Genomics Technology
a. Create cDNA resources of both human and model organisms
b. Develop improved technologies for analysis of noncoding sequences
c. Generate methods and technologies for comprehensive analysis of gene expression
d. Develop technologies for creating genome-wide mutations and analyzing the results
e. Develop experimental and computational means for global protein analysis
c Goal 5: Comparative Genomics
a. Complete the C. elegans genome sequence in 1998
b. Complete the Drosophila genome sequence by 2002 (or earlier because of anticipated work in the private sector)
c. Develop genomic resources for the mouse
i. Develop an integrated physical and genetic map
ii. Develop cDNA resources
iii. Complete the mouse genome sequence by 2008 (or earlier given lessons and new technologies from Goals 1 and 2)
d. Identify other model organisms of great use to understanding the human genome or that will significantly aid in other
genomic studies
c Goal 6: Ethical, Legal, and Social Implications (ELSI)
a. Analyze implications resulting from extensive information about human sequence and its variation
b. Examine issues involved in integration of genetic technologies and information into health care and public health
activities
c. Examine issues involved in integration of knowledge about genomics and gene-environment interactions into
nonclinical and research settings
d. Explore interaction of genetic knowledge, philosophy, theology, and ethics
e. Explore ways in which racial, ethnic, and socioeconomic issues affect genetic research, services, and policy
development
c Goal 7: Bioinformatics and Computation Biology
a. Improve database content and utility
b. Develop better tools for data generation, capture, and annotation
c. Develop and improve tools and databases for comprehensive functional studies
d. Develop and improve tools for representing and analyzing sequence similarity and variation
e. Develop and support effective approaches to produce robust, exportable software that can be widely shared
c Goal 8: Manpower and Training
a. Nurture training of scientists skilled in genomics research
b. Encourage establishment of academic career paths for genomic scientists
c. Increase number of scholars with knowledge in both genomic and genetic sciences and in ethics, law, or social
sciences
*Information obtained from draft of the New Goals for the U.S. Human Genome Project 1998–2003, as provided at the September 14, 1998 public
forum meeting of the NHGRI advisory council. Complete content available in the October 23, 1998 issue of Science.
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cerns about what effect having large
amounts of DNA information tied up in
intellectual property rights will have on
the public welfare are still unresolved.
The second new addition to the plan
is the generation of what is being called
a ‘‘working draft’’ of the human genome
by 2001. This draft will be based on
mapped clones that provide at least 90%
coverage of the genome, will have a 99%
accuracy, and should be quite useful for
finding genes. The one issue stressed
about this working draft is that it is a
stage that must be passed through in the
progress toward the final sequenced ge-
nome goal. This was an essential com-
ponent of the plan, as no one wanted to
shunt money into generating a quick,
low-quality version of the genome se-
quence that would ultimately be dis-
carded once the completed version
could take its place. The concern here is
twofold: (1) the perceived waste of
money in generating something that
would ultimately be discarded and (2)
the potential that the lower-quality ver-
sion could possibly be chosen as an er-
satz final version were it deemed appro-
priate by individuals with narrower
goals for the use of the sequence.
The Gold-Standard Version of the se-
quence proposed for 2003 does retain a
few caveats, which the board was careful
in trying to define. Several committee
members expressed concern that 2003
would arrive and, without a more de-
tailed indication of what a ‘‘finished’’ se-
quence was, there was always the poten-
tial to simply claim the human genome
sequence complete. As indicated by a
footnote in the proposal, the board ex-
pects that there will remain some re-
gions (an indeterminate, though likely
rare, number) that will prove difficult to
clone and sequence. The other regions
not likely to be finished by 2003 include
highly repeated sequences in the centro-
meres and constitutive heterochromatic
regions. Thus, the complete sequence
for the human genome in 2003 is ex-
pected to retain some gaps that require
closure. The completed sequence there-
fore refers to that portion of human
DNA that can be stably cloned and se-
quenced by current technology.
Not Just Sequence
Publicly funded projects embrace a great
deal beyond just determining the hu-
man genome sequence. Thus any com-
parison of money spent and completion
of goals by privately and publicly
funded projects must take into account
the additional aspects provided by each.
That the 5-year plan for the human
genome project covers more than just
human genome sequencing per se is
made immediately apparent by the fact
that Goal 1 covers the completion of the
human genome sequence, whereas
Goals 2–8 cover all the additional com-
ponents that are also under the umbrella
of the publicly funded Human Genome
Project (see Box 1). These areas have
long-term impact not only on the
simple achievement of the completion
of the human genome sequence by the
desired date, but on our ability to under-
stand and use this information.
New technology, better methodolo-
gies, and more advanced bioinformatics
analysis tools and resources are required
for progress in sequencing capability.
This is not only essential to meet the
2003 completion date, but also to estab-
lish efficient and inexpensive means to
continue to utilize high-throughput se-
quencing technology for additional ex-
perimental purposes beyond this date.
Genomic studies in model organisms,
comparative studies, and further bioin-
formatics advances are absolutely re-
quired to aid in deciphering genome se-
quences (from gene identification to
gene function) and in dissecting whole
chomosome function, evolution, and
activity. The biological community in
general has made tremendous use of EST
resources and will benefit more so from
planned cDNA libaries, cell line, and
DNA sample libraries. Obviously, an en-
tire highly trained work force is required
to carry out these plans, and training,
funding, and encouraging establish-
ment of such skilled individuals is there-
fore included in the goals defined for
the next 5 years. Finally, all this work
and planning could be worth very little
if the public ultimately rejects the po-
tential benefits from the genome
projects because of misconceptions or
fear of the potential misuse or abuse of
this newfound knowledge. Thus, the im-
portance of the ethical, legal, and social
Implications (ELSI) programs can not be
overstated. Scientists and the general
public must come together in making
decisions about how this information is
to be used in both clinical and nonclini-
cal settings.
Taking the entire new 5-year plan
in at a glance, ‘‘bold’’ may be too tame a
word.
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